Concord Biotech will open for subscription on August 4. The company is backed by Rakesh Jhunjhunwala's RARE Enterprises. The company was incorporated in 1984. Concord Biotech Limited is an India-based R&D-driven biopharma company. It supplies products to over 70 countries & 200+ customers. The company manufactures API through fermentation & semi-synthetic process and finished formulations. It also manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals. Ankita Saxena tells you all you need to know about the IPO.
#concordipo #concordbiotech #ipo2023
Subscribe To ET Now For Latest Updates On Stocks, share market, business News, Trading, Crypto Updates | [ Ссылка ]
To Stay Updated Download the Times Now App :-
Android Google Play : [ Ссылка ]
Apple App Store : [ Ссылка ]
Social Media Links :-
Twitter - [ Ссылка ]
Facebook - [ Ссылка ]
G+ - [ Ссылка ]
Website - www.etnownews.com
Subscribe Now To Our Network Channels:-
Times Now: [ Ссылка ]
Mirror Now: [ Ссылка ]
